Search

Displaying results 191 - 200 of 4018 in total
  1. Drug

    Darolutamide

    go.drugbank.com/drugs/DB12941
    ApprovedInvestigational

    Darolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). … [A189054,A189063] Darolutamide was developed by Bayer HealthCare Pharmaceuticals Inc. and approved by the FDA on July 30th, 2019.[L10887]

    Categories: Antiandrogens, non-steroidal
  2. Drug

    Technetium Tc-99m oxidronate

    go.drugbank.com/drugs/DB09139
    ApprovedWithdrawn

    [L1140] It was developed by Mallinkrodt nuclear and FDA approved on February 18, 1981. … [L1137] The radiopharmaceuticals based on technetium-99m are widely used for diagnostic purposes because 99mTc has a versatile chemistry which allows it to produce an extense variety of complexes with

  3. Drug

    Ibandronate

    go.drugbank.com/drugs/DB00710
    ApprovedInvestigational

    [L13805,L13808] Ibandronate was first described in the literature in 1993 as a treatment for bone loss in dogs.[A203138] Ibandronate was granted FDA approval on 16 May 2003.[L13805]

    Categories: Bone Density Conservation Agents, Drugs for Treatment of Bone DiseasesProducts: BONDRONAT 6MG KON HER INF, ICIN KON. COZ. ICEREN FLAKON
  4. Drug

    Idecabtagene vicleucel

    go.drugbank.com/drugs/DB16665
    ApprovedInvestigational

    [L32858] Idecabtagene vicleucel was approved by the FDA on March 26, 2021 [L32863] and by the EMA on August 18, 2021.[L51003] … [A232563] These cancerous cells generally express the B-cell maturation antigen, while it is rarely expressed on non-cancerous cells.

  5. Drug

    Romosozumab

    go.drugbank.com/drugs/DB11866
    ApprovedInvestigational

    Romosozumab prevents bone resorption and induces the formation of bone though it is associated with an increased risk of cardiac death, heart attack, and stroke in one study[L5921,L5924]. … Romosozumab also demonstrates a faster and larger increase in bone density than teriparatide[A177050]. Romosozumab is marketed in the United States by Amgen under the brand name Evinity[L5921].

    Categories: Bone Anabolic Agents, Drugs for Treatment of Bone Diseases
  6. Drug

    Tolbutamide

    go.drugbank.com/drugs/DB01124
    Approved

    Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). … Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor.

  7. Indication

    Bone Marrow Suppression caused by Chemotherapy

    go.drugbank.com/conditions/DBCOND0137031
    Drugs: Trilaciclib
    Synonyms: Bone Marrow Suppression caused by Chemotherapy
  8. Drug

    Doxercalciferol

    go.drugbank.com/drugs/DB06410
    ApprovedInvestigational

    Doxercalciferol is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis, as well as for the treatment of secondary hyperparathyroidism in patients

    Categories: Bone Density Conservation Agents
  9. Drug

    Retifanlimab

    go.drugbank.com/drugs/DB15766
    ApprovedInvestigational

    [L45608,L45618] On March 2023, the FDA granted accelerated approval to retifanlimab for a different indication, the treatment of metastatic or recurrent locally advanced Merkel cell carcinoma (MCC). … On October 2021, Incyte Biosciences withdrew its application for a marketing authorization of retifanlimab for the treatment of squamous carcinoma of the anal canal.

  10. Drug

    Betamethasone phosphate

    go.drugbank.com/drugs/DB14669
    ApprovedVet approved

    [L11994] Betamethasone sodium phosphate was granted FDA approval on 3 March 1965.[L11994]